CHICAGO — Glucagon-like peptide-1 receptor agonists lowered the risk for obesity-related cancers compared with bariatric surgery among individuals with a BMI of at least 35, according to data presented at ASCO Annual Meeting. Treatment with glucagon-like peptide-1 receptor agonists (GLP-1 RAs) conferred a greater risk reduction in all-cause mortality, despite inferior weight loss results
/PRNewswire/ Winners from the American Liver Foundation s 2023 Liver Health Poster Competition were announced today. This competition showcases posters and.